Introduction: acute myeloid leukemia (AML) is a clonal disorder originating from bone marrow (BM)-derived leukemic stem cells and characterized by a high relapse rate. The role of the immune system in AML progression and treatment response remains incompletely understood. This study aimed to identify immune signatures associated with AML burden and phenotype. Methods: BM samples from 44 AML patients at diagnosis and 11 healthy donors (HDs) were analyzed by multiparametric flow cytometry using a lineage-based gating strategy. Major immune cell populations, including T-, B-, NK-cell, monocytes, dendritic cell (DC), and myeloid-derived suppressor cell (MDSC) subsets, together with immune checkpoint molecules, were evaluated. AML blasts were characterized by CD34, CD117, CD33, CD13, HLA-DR, CD7, CD56, and CD25 expression. Longitudinal analyses were performed in 17 relapsed/refractory (R/R) patients following immunotherapy or chemotherapy. Results: at diagnosis, AML patients showed significantly increased frequencies of naïve CD4+ T cells, regulatory T cells (Tregs), plasmacytoid DCs, and monocytic DCs, whereas regulatory B cells (Bregs) and terminal NK cells were markedly reduced compared with HDs. Immune checkpoint analysis revealed increased expression of TIM1, CD244, and TIGIT on naïve B cells, T cells, and Tregs, respectively. A trend toward increased LOX1 expression was observed in MDSC subsets, while Bregs displayed enhanced CD1D expression. Following therapy, R/R patients showed significant reductions in CD8+ T cells, double-negative B cells, and Bregs compared with baseline. Checkpoint analysis demonstrated decreased expression of TIGIT/CD39 on Tregs, TIGIT/PD1 on B-cell subsets, and TIGIT/PD1 on intermediate effector-memory CD4+ T cells, whereas TIGIT expression increased in effector-memory CD8+ T-cell subsets. Correlation analyses revealed a close association between AML burden and immune exhaustion. At diagnosis, AML burden correlated with increased CTLA4/PD1 expression on CD4+ T-cell subsets and Tregs. Furthermore, CD25+ AML cells were associated with PD1/LAG3/TIGIT expression, while CD56+ AML cells correlated with TIGIT/TIM3 expression on CD4+ T-cell subsets. In R/R patients, AML burden correlated with PD1/CTLA4/LAG3 expression on T-cell subsets. Notably, CD25+ AML cells were associated with PD1-expressing NK and B-cell subsets and TIGIT+ Tregs, whereas CD56+ AML cells correlated with TIM1/TIGIT/PD1 expression on B-cell subsets and PD1/BTLA expression on CD4+ T-cell subsets. CD7+ AML cells were associated with LAG3/TIM3 expression on CD4+ T cells and CTLA4/PD1/LAG3/TIM3 expression on Tregs. Conclusions: These findings demonstrate a strong association between AML burden, aberrant AML phenotypes, and an immunosuppressive microenvironment characterized by immune checkpoint upregulation, supporting the development of novel immunotherapeutic strategies.
Fincato, N., Tespio, G., Chirumbolo, G., Forte, D., Nanni, J., Zingarelli, F., et al. (2026). Comprehensive profiling of the bone marrow microenvironment reveals an exhausted immune signature associated with tumor burden in acute myeloid leukemia.
Comprehensive profiling of the bone marrow microenvironment reveals an exhausted immune signature associated with tumor burden in acute myeloid leukemia
Nicole Fincato;Giusy Tespio;Gabriella Chirumbolo;Dorian Forte;Federico Zingarelli;Alessandra Grassi;Emanuela Ottaviani;Pier Luigi Zinzani;Antonio Curti;Lucia Catani;Martina Barone
2026
Abstract
Introduction: acute myeloid leukemia (AML) is a clonal disorder originating from bone marrow (BM)-derived leukemic stem cells and characterized by a high relapse rate. The role of the immune system in AML progression and treatment response remains incompletely understood. This study aimed to identify immune signatures associated with AML burden and phenotype. Methods: BM samples from 44 AML patients at diagnosis and 11 healthy donors (HDs) were analyzed by multiparametric flow cytometry using a lineage-based gating strategy. Major immune cell populations, including T-, B-, NK-cell, monocytes, dendritic cell (DC), and myeloid-derived suppressor cell (MDSC) subsets, together with immune checkpoint molecules, were evaluated. AML blasts were characterized by CD34, CD117, CD33, CD13, HLA-DR, CD7, CD56, and CD25 expression. Longitudinal analyses were performed in 17 relapsed/refractory (R/R) patients following immunotherapy or chemotherapy. Results: at diagnosis, AML patients showed significantly increased frequencies of naïve CD4+ T cells, regulatory T cells (Tregs), plasmacytoid DCs, and monocytic DCs, whereas regulatory B cells (Bregs) and terminal NK cells were markedly reduced compared with HDs. Immune checkpoint analysis revealed increased expression of TIM1, CD244, and TIGIT on naïve B cells, T cells, and Tregs, respectively. A trend toward increased LOX1 expression was observed in MDSC subsets, while Bregs displayed enhanced CD1D expression. Following therapy, R/R patients showed significant reductions in CD8+ T cells, double-negative B cells, and Bregs compared with baseline. Checkpoint analysis demonstrated decreased expression of TIGIT/CD39 on Tregs, TIGIT/PD1 on B-cell subsets, and TIGIT/PD1 on intermediate effector-memory CD4+ T cells, whereas TIGIT expression increased in effector-memory CD8+ T-cell subsets. Correlation analyses revealed a close association between AML burden and immune exhaustion. At diagnosis, AML burden correlated with increased CTLA4/PD1 expression on CD4+ T-cell subsets and Tregs. Furthermore, CD25+ AML cells were associated with PD1/LAG3/TIGIT expression, while CD56+ AML cells correlated with TIGIT/TIM3 expression on CD4+ T-cell subsets. In R/R patients, AML burden correlated with PD1/CTLA4/LAG3 expression on T-cell subsets. Notably, CD25+ AML cells were associated with PD1-expressing NK and B-cell subsets and TIGIT+ Tregs, whereas CD56+ AML cells correlated with TIM1/TIGIT/PD1 expression on B-cell subsets and PD1/BTLA expression on CD4+ T-cell subsets. CD7+ AML cells were associated with LAG3/TIM3 expression on CD4+ T cells and CTLA4/PD1/LAG3/TIM3 expression on Tregs. Conclusions: These findings demonstrate a strong association between AML burden, aberrant AML phenotypes, and an immunosuppressive microenvironment characterized by immune checkpoint upregulation, supporting the development of novel immunotherapeutic strategies.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



